Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT06372964

PHASE3

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

Sponsor: Intra-Cellular Therapies, Inc.

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).

Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Lumateperone for the Treatment of Major Depressive Episodes (MDEs) Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) in Pediatric Patients Aged 10 to 17 Years

Key Details

Gender

All

Age Range

10 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

384

Start Date

2024-05-13

Completion Date

2027-05

Last Updated

2025-07-08

Healthy Volunteers

Conditions

Bipolar Depression

Interventions

DRUG

Lumateperone

Lumateperone administered orally, once daily.

DRUG

Placebo

Matching placebo administered orally, once daily.

Inclusion Criteria: 1. Able to provide consent as follows: * The Legally Authorized Representative (LAR) must provide written, informed consent. * The patient must provide written assent; 2. Male or female patients 10 to 17 years of age, inclusive; 3. Have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Text Revision (DSM-5-TR) primary diagnosis of bipolar I or bipolar II disorder with a current MDE without psychosis as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL); 4. Subject has a lifetime history of at least one manic or hypomanic episode. 5. Subject's current major depressive episode is ≥ 4 weeks and less than 12 months in duration; 6. CDRS-R total score ≥ 45 with ≥ 5 on Item 11 (depressed feelings) at Screening and Baseline; 7. Young Mania Rating Scale (YMRS) score ≤ 15 (with YMRS Item 1 \[elevated mood\] score ≤ 2) at Screening and Baseline. Exclusion Criteria: 1. Has a primary psychiatric diagnosis other than bipolar I or bipolar II disorder. Exception includes: * Attention deficit hyperactivity disorder (ADHD). If a subject is taking medications for ADHD, they must have been on a stable treatment regimen of these medication(s) for 30 days prior to screening and the treatment regimen is expected to remain stable throughout the study. 2. Intellectual disability based on Investigator opinion and DSM-5 criteria 3. Patient has been hospitalized for a bipolar manic episode within the 30 days prior to randomization; 4. Demonstrates a ≥ 25% decrease (improvement) in the CDRS-R total score between Screening and Baseline visits, or the CDRS-R is below 45 at Baseline; 5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during his/her participation in the study or 1. At Screening, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening or, at Baseline, the patient scores "yes" on Suicidal Ideation Items 3, 4, or 5 since the Screening Visit; 2. At Screening, the patient has had 1 or more suicidal attempts within the 2 years prior to Screening; or 3. At Screening or Baseline, scores \> 3 on Item 13 (suicidal ideation) on the CDRS-R; or 4. The patient is considered to be an imminent danger to him/herself or others.

Locations (59)

Clinical Site

Dothan, Alabama, United States

Clinical Site

Little Rock, Arkansas, United States

Clinical Site

Anaheim, California, United States

Clinical Site

Redlands, California, United States

Clinical Site

Sacramento, California, United States

Clinical Site

San Diego, California, United States

Clinical Site

West Covina, California, United States

Clinical Site

Colorado Springs, Colorado, United States

Clinical Site

Gainesville, Florida, United States

Clinical Site

Hialeah, Florida, United States

Clinical Site

Homestead, Florida, United States

Clinical Site

Miami, Florida, United States

Clinical Site

Miami, Florida, United States

Clinical Site

Miami, Florida, United States

Clinical Site

Miami, Florida, United States

Clinical Site

Miami, Florida, United States

Clinical Site

Miami, Florida, United States

Clinical Site

Miami, Florida, United States

Clinical Site

Miami, Florida, United States

Clinical Site

Miami, Florida, United States

Clinical Site

Miami Gardens, Florida, United States

Clinical Site

Miami Lakes, Florida, United States

Clinical Site

Miami Lakes, Florida, United States

Clinical Site

Miami Springs, Florida, United States

Clinical Site

Orlando, Florida, United States

Clinical Site

West Palm Beach, Florida, United States

Clinical Site

Atlanta, Georgia, United States

Clinical Site

Decatur, Georgia, United States

Clinical Site

Lawrenceville, Georgia, United States

Clinical Site

Savannah, Georgia, United States

Clinical Site

Chicago, Illinois, United States

Clinical Site

Indianapolis, Indiana, United States

Clinical Site

Baltimore, Maryland, United States

Clinical Site

Bloomfield Hills, Michigan, United States

Clinical Site

Saint Charles, Missouri, United States

Clinical Site

Lincoln, Nebraska, United States

Clinical Site

Kinston, North Carolina, United States

Clinical Site

Avon Lake, Ohio, United States

Clinical Site

Cincinnati, Ohio, United States

Clinical Site

Garfield, Ohio, United States

Clinical Site

Westlake, Ohio, United States

Clinical Site

Oklahoma City, Oklahoma, United States

Clinical Site

Oklahoma City, Oklahoma, United States

Clinical Site

Austin, Texas, United States

Clinical Site

Flower Mound, Texas, United States

Clinical Site

Frisco, Texas, United States

Clinical Site

Houston, Texas, United States

Clinical Site

Houston, Texas, United States

Clinical Site

Richmond, Texas, United States

Clinical Site

Richmond, Virginia, United States

Clinical Site

Bellevue, Washington, United States

Clinical Site

Everett, Washington, United States

Clinical Site

Ahmedabad, India

Clinical Site

Aurangabad, India

Clinical Site

Nashik, India

Clinical Site

Varanasi, India

Clinical Site

Belgrade, Serbia

Clinical Site

Niš, Serbia

Clinical Site

Novi Sad, Serbia

Clinical Research Directory

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (59)